PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1135-1141

  Liu, Yongjian ^a   Pierce, Richard ^b   Luehmann, Hannah P ^a   Sharp, Terry L ^a   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Chemokine receptors; Molecular imaging; Positron emission tomography; Virus macrophage inflammatory protein

Indexed keywords

APOLIPOPROTEIN E; CARBON MONOXIDE O 15; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; VIRAL MONOCYTE CHEMOTACTIC PROTEIN 2 DOTA CU 64;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VOLUME; CONTROLLED STUDY; FEMORAL ARTERY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; TISSUE DISTRIBUTION;

ATHEROSCLEROSIS; CHEMOKINE RECEPTORS; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; VIRUS MACROPHAGE INFLAMMATORY PROTEIN;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHEMOKINES; FEMORAL ARTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR IMAGING; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, CHEMOKINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84879891254     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.114777     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics: 2012 update - a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Majmudar MD, Nahrendorf M. Cardiovascular molecular imaging: the road ahead. J Nucl Med. 2012;53:673-676.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
4. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
5. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138.
6. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111:231-244.
7. Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J Nucl Med. 2010;51(suppl 1):51S-65S.
8. Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. Bioconjug Chem. 2012;23:671-682.
9. Liu Y, Abendschein D, Woodard GE, et al. Molecular imaging of atherosclerotic plaque with 64Cu-labeled natriuretic peptide and PET. J Nucl Med. 2010;51:85-91.
10. Libby P, DiCarli M, Weissleder R. The vascular biology of atherosclerosis and imaging targets. J Nucl Med. 2010;51(suppl 1):33S-37S
11. Joshi F, Rosenbaum D, Bordes S, Rudd JH. Vascular imaging with positron emission tomography. J Intern Med. 2011;270:99-109.
12. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol. 2010;7:38-47.
13. Ross R. Atherosclerosis: an inflammatory disease.N Engl JMed. 1999;340:115-126.
14. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
15. Jerath MR, Kwan M, Liu P, Patel DD. Chemokine receptors in atherosclerosis. In: Harrison JK, Lukacs NW, eds. The Chemokine Receptors. Totowa, NJ: Humana Press; 2007:199-233.
16. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood. 2000;95:3032-3043.
17. Gerszten RE, Tager AM. The monocyte in atherosclerosis: should I stay or should I go now? N Engl J Med. 2012;366:1734-1736.
18. McPherson R, Davies RW. Inflammation and coronary artery disease: insights from genetic studies. Can J Cardiol. 2012;28:662-666.
19. Schieffer B, Luchtefeld M. Emerging role of chemokine receptor 7 in atherosclerosis. Trends Cardiovasc Med. 2011;21:211-216.
20. Koenen RR, Weber C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med. 2011;3:713-725.
21. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov. 2010;9:141-153.
22. Potteaux S, Combadiere C, Esposito B, et al. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26: 1858-1863.
23. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162:1453-1469.
24. Buettner C, Rudd JH, Fayad ZA. Determinants of FDG uptake in atherosclerosis. JACC Cardiovasc Imaging. 2011;4:1302-1304.
25. Lüttichau HR, Johnsen AH, Jurlander J, Rosenkilde MM, Schwartz TW. Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3. J Biol Chem. 2007;282:17794-17805.
26. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997;277:1656-1659.
27. McCarthy DW, Shefer RE, Klinkowstein RE, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
28. Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol. 2007;27:2079-2093.
29. Zhang J, Nie L, Razavian M, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation. 2008;118:1953-1960.
30. Liu Y, Ibricevic A, Cohen JA, et al. Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm. 2009;6:1891-1902.
31. Mathias CJ, Welch MJ, Green MA, et al. In vivo comparison of copper bloodpool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med. 1991;32:475-480.
32. Liu Y, Pressly ED, Abendschein DR, et al. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J Nucl Med. 2011;52: 1956-1963.
33. Lehtiö K, Oikonen V, Gronroos T, et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [15O]H2O and [18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
34. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol. 1990;15:1667-1687.
35. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol. 2010;88:41-55.
36. Ferrante EA, Pickard JE, Rychak J, Klibanov A, Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release. 2009;140:100-107.
37. Haider N, Hartung D, Fujimoto S, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol. 2009;16:753-762.
38. McAteer MA, Schneider JE, Ali ZA, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol. 2008;28:77-83.
39. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010;86:192-201.
40. Sheikine Y, Akram K. FDG-PET imaging of atherosclerosis: do we know what we see? Atherosclerosis. 2010;211:371-380.